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Inflammation, Aspirin, and the Risk 
of Cardiovascular Disease
 
To the Editor:
 
 Ridker and colleagues (April 3 issue)
 
1
 
 have
provided important new information that will be useful in
assessing the risk of cardiovascular events and in optimiz-
ing prophylaxis. Both Ridker et al. and Maseri, in his edi-
torial,
 
2
 
 speculate that the antiinflammatory effects of aspi-
rin may be important in reducing the risk of myocardial
infarction when the level of C-reactive protein is high.
It seems unlikely that the antiinflammatory effects of as-
pirin have an important role, since these effects are minus-
cule and short-lived at the dosage used in the study by
Ridker et al. (325 mg every other day). Were these effects
of aspirin indeed important, higher doses would be ex-
pected to confer a greater cardioprotective effect. I am not
aware of any controlled study that has demonstrated a
greater effect with higher doses.
An alternative possibility is that an elevated level of
C-reactive protein is associated with increased coagulabili-
ty (local or systemic, or both) and that the cardioprotec-
tive effects of aspirin are proportional to the magnitude of
this increase in coagulability.
W
 
ILLIAM
 
 M. M
 
URRAY
 
, M.D.
 
5020 Ritter Rd.
Mechanicsburg, PA 17055
 
1.
 
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. In-
flammation, aspirin, and the risk of cardiovascular disease in apparently 
healthy men. N Engl J Med 1997;336:973-9.
 
2.
 
Maseri A. Inflammation, atherosclerosis, and ischemic events — explor-
ing the hidden side of the moon. N Engl J Med 1997;336:1014-6.
 
To the Editor:
 
 The report by Ridker et al. adds further
support to the response-to-injury hypothesis proposed 20
years ago by Ross et al.
 
1
 
 However, the conclusion that the
benefits of aspirin arise, at least in part, from its antiinflam-
matory activity is difficult to accept. A dose of one aspirin
tablet every other day can hardly be considered an antiin-
flammatory regimen of the drug. The short (15-minute)
biologic half-life of aspirin adds to the doubt. The salicy-
late resulting from the degradation of aspirin is a very
weak contributor to its antiinflammatory effects.
It still seems probable that the unique properties of
both aspirin and platelets — namely, aspirin’s acetylation
of the enzyme cyclooxygenase and a platelet’s inability to
synthesize the new enzyme — are responsible for all the
antithrombotic effects observed.
J
 
OHN
 
 J. B
 
RUNO
 
, P
 
H
 
.D.
 
17 Oyster Landing Rd.
Hilton Head Island, SC 29928
 
1.
 
Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am 
J Pathol 1977;86:675-84.
 
To the Editor:
 
 Ridker and colleagues report that in their
study the effect of aspirin on the risk of cardiovascular dis-
ease was largely confined to patients with elevated C-reac-
tive protein levels and that an elevated level of C-reactive
protein was associated with arterial but not venous throm-
bosis. The authors hypothesize that the benefits of aspirin
in this subgroup reflect antiinflammatory rather than anti-
platelet effects of this agent. We suggest an alternative hy-
pothesis.
Platelets are inflammatory cells.
 
1
 
 In evolutionary terms,
platelets are derived from hemocytes — single circulatory
blood cells with the combined functions of participating
in the inflammatory response, oxygen carriage, and hemo-
stasis.
 
2
 
 Activated platelets secrete numerous proinflam-
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matory molecules, including thromboxane A
 
2
 
, which is
blocked by aspirin.
The association of platelet activation with the inflamma-
tory process is well documented in inflammatory bowel
disease.
 
3
 
 Platelet activation may contribute to the micro-
vascular thrombosis and infarction reported in association
with this condition.
With regard to the link between interleukin-6 and
C-reactive protein, to which the authors refer, it should be
noted that interleukin-6 has a stimulatory effect on mega-
karyocytes
 
4
 
 and may thus be linked to alterations of plate-
let function.
For these reasons, we propose that in further work ad-
dressing these intriguing observations, researchers should
avoid a spurious dichotomy between the thrombotic and
inflammatory effects of platelets.
M
 
ARY
 
 R. C
 
AHILL
 
, M.D.
 
Royal London Hospital
London E1 1BB, United Kingdom
 
I
 
VAN
 
 J. P
 
ERRY
 
, M.D., P
 
H
 
.D.
 
University College
Cork, Ireland
 
1.
 
Page CP. Platelets as inflammatory cells. Immunopharmacology 1989;
17:51-9.
 
2.
 
Iwanaga S. Primitive coagulation systems and their message to modern 
biology. Thromb Haemost 1993;70:48-55.
 
3.
 
Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate 
in an activated state in inflammatory bowel disease. Gastroenterology 
1994;106:840-5.
 
4.
 
Wong GG, Witek-Giannotti JS, Temple PA, et al. Stimulation of murine 
hemopoietic colony formation by human IL-6. J Immunol 1988;140:
3040-4.
 
To the Editor:
 
 The study reported by Ridker et al. shows
that C-reactive protein, as an acute-phase reactant, predicts
the risk of myocardial infarction and stroke. However,
this study was mostly concerned with the serum level of
C-reactive protein as an inflammatory marker, and there is
no mention of its presence in the normal and atheroscle-
rotic arterial wall in humans.
 
1,2
 
 We have previously meas-
ured the level of C-reactive protein eluted from the human
arterial wall with different degrees of atherosclerosis.
 
1
 
 Fatty
streaks and uncomplicated fibrous plaques contained the
highest levels of C-reactive protein. Lower levels were
found in areas of intimal thickening, and only a few nor-
mal areas contained the protein.
 
1,2
 
 
The accumulation of C-reactive protein in the athero-
sclerotic wall suggests a local inflammatory event. It is dif-
ficult to establish whether the protein is produced locally
or derived from the circulation, but both mechanisms are
involved in the accumulation of most of the proteins
present in the arterial wall. We found that C-reactive pro-
tein was localized around the foam cells of fatty streaks,
suggesting its local synthesis.
 
3
 
 For such a strongly respon-
sive and potent acute-phase reactant as C-reactive protein,
the small but constant and clinically significant increase in
its plasma levels, as Ridker et al. observed in their study,
may suggest its slow release from the arterial wall with ath-
erosclerotic lesions.
It is also important to mention that not only C-reactive
protein but also other acute-phase reactants, such as com-
plement proteins C3, C4, and C9, as well as important in-
flammatory cytokines, such as interleukin-6 and interleu-
kin-8, are accumulated in the atherosclerotic wall.
 
1,3,4
 
 The
complement system, which is an important immune effec-
tor, is present in the arterial wall in its activated form, and
this is an important observation, since C-reactive protein
is one of its known potent activators.
 
3
 
Thus, C-reactive protein seems to be directly involved in
promoting local inflammation by activating other media-
tors. Its increased concentration in plasma and clinically
predictive role should be correlated and indeed reflect, as
shown by Ridker et al., events occurring at the level of the
arterial wall, where inflammation is responsible for the
progression of the atherosclerotic lesion.
H
 
OREA
 
 R
 
US
 
, M.D., P
 
H
 
.D.
F
 
LORIN
 
 I. N
 
ICULESCU
 
, M.D., P
 
H
 
.D.
 
University of Maryland School of Medicine
Baltimore, MD 21201
 
1.
 
Vlaicu R, Rus HG, Niculescu F, Cristea A. Immunoglobulins and com-
plement components in human aortic atherosclerotic intima. Atherosclero-
sis 1985;55:35-50.
 
2.
 
Reynolds GD, Vance RP. C-reactive protein immunohistochemical lo-
calization in normal and atherosclerotic human aortas. Arch Pathol Lab 
Med 1987;111:265-9.
 
3.
 
Niculescu F, Rus HG, Vlaicu R. Immunohistochemical localization of 
C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with 
atherosclerosis. Atherosclerosis 1987;65:1-11.
 
4.
 
Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein 
and gene expression in human arterial atherosclerotic wall. Atherosclerosis 
1996;127:263-71.
 
The authors reply:
 
To the Editor:
 
 Dr. Murray raises the intriguing possibility
that our observations are attributable to an association be-
tween C-reactive protein and hypercoagulability. This hy-
pothesis, however, is not supported by our finding that
there was no association between C-reactive protein and
venous thrombosis, a disease more closely linked to hyper-
coagulability than to atherothrombosis.
Dr. Bruno suggests that the antithrombotic effects of
aspirin may explain our results and that the apparent in-
crease in the efficacy of aspirin across quartiles of C-reac-
tive protein simply reflects a greater benefit among those
at greater risk. In prior reports on aspirin from the Physi-
cians’ Health Study, we observed no greater benefits in
higher-risk subgroups.
 
1,2
 
We concur with Drs. Murray and Bruno that the short
half-life of aspirin renders a conventional antiinflammatory
contribution from this agent less likely. Our data do raise
the question of whether this contribution is adequate for
microinflammatory inhibition. In this regard, the points
made by Drs. Cahill and Perry, that platelets themselves
can be considered inflammatory cells and that they secrete
proinflammatory molecules, are of considerable interest.
The possibility that aspirin has different effects in dif-
ferent thrombotic settings, such as those associated with
plaque rupture as compared with endothelial erosion,
 
3
 
is supported by the observations of Drs. Rus and Nicules-
cu regarding the presence of C-reactive protein within
the atherosclerotic arterial wall.
 
4
 
 Whether this accumula-
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tion is more or less apparent in lesions associated with
plaque rupture is also an important question to be inves-
tigated.
P
 
AUL
 
 M. R
 
IDKER
 
, M.D.
C
 
HARLES
 
 H. H
 
ENNEKENS
 
, M.D.
 
Brigham and Women’s Hospital
Boston, MA 02215-1204
 
1.
 
Steering Committee of the Physicians’ Health Study Research Group. 
Final report on the aspirin component of the ongoing Physicians’ Health 
Study. N Engl J Med 1989;321:129-35.
 
2.
 
Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A pro-
spective study of cholesterol, apolipoproteins, and the risk of myocardial 
infarction. N Engl J Med 1991;325:373-81.
 
3.
 
van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal 
rupture or erosion of thrombosed coronary atherosclerotic plaques is char-
acterized by an inflammatory process irrespective of the dominant plaque 
morphology. Circulation 1994;89:36-44.
 
4.
 
Vlaicu R, Rus HG, Niculescu F, Cristea A. Immunoglobulins and com-
plement components in human aortic atherosclerotic intima. Atherosclero-
sis 1985;55:35-50.
 
To the Editor: 
 
Dr. Murray’s timely letter offers me the
opportunity to comment further on the progressive reduc-
tion of the risk of myocardial infarction with increasing
levels of C-reactive protein in patients taking 325 mg of
aspirin on alternate days.
 
1
 
 I agree with Dr. Murray that the
available evidence is against the hypothesis that aspirin acts
as an antiinflammatory drug because of its short plasma
half-life and because inflammatory cells can resynthesize
cyclooxygenase.
Unpublished data from our group indicate that both in
patients with stable angina and in those with unstable
angina, the increase in serum C-reactive protein levels in
response to diverse inflammatory stimuli is proportional
to the base-line levels of C-reactive protein. Thus, the
base-line values may be markers of a variable individual
propensity for an enhanced acute-phase response. The
hyperresponsiveness of acute-phase reactants can result
in enhanced production and an enhanced effect of pro-
thrombotic inflammatory cytokines, which under some
conditions may contribute to the development of unsta-
ble angina, myocardial infarction, and stroke. This hy-
pothesis may link the long-term prognostic value of
C-reactive protein levels within the normal range (as ob-
served in the Physicians’ Health Study
 
1
 
) and the prognos-
tic value of mildly elevated levels in patients with stable
ischemic heart disease
 
2
 
 or unstable angina at the time of
hospital discharge
 
3
 
 with the short-term in-hospital prog-
nostic value of markedly elevated levels of C-reactive pro-
tein in patients with unstable angina.
 
4
 
 Moreover, my col-
leagues and I failed to observe significant differences in
cytomegalovirus and 
 
Helicobacter pylori
 
 serum antibody
titers between patients with chronic ischemic syndromes
and those with acute ischemic syndromes.
 
5
 
 Therefore, the
greater effect of aspirin in persons in the higher quartiles
of the normal range of C-reactive protein in the Physi-
cians’ Health Study
 
1
 
 is not easily explainable. Since the
confidence limits for the risk reduction in the four groups
may overlap, the differences may simply be due to the fact
that the reduction in risk was more easily detectable in the
higher-risk group than in the lower-risk group. However,
this intriguing finding should be confirmed by other stud-
ies before there is extensive discussion about its possible
interpretation.
A
 
TTILIO
 
 M
 
ASERI
 
, M.D.
 
Catholic University of the Sacred Heart
00168 Rome, Italy
 
1.
 
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. In-
flammation, aspirin, and the risk of cardiovascular disease in apparently 
healthy men. N Engl J Med 1997;336:973-9.
 
2.
 
Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. 
Hemostatic factors and the risk of myocardial infarction or sudden death 
in patients with angina pectoris. N Engl J Med 1995;332:635-41.
 
3.
 
Liuzzo G, Biasucci LM, Buffon A, et al. Elevated C-reactive protein at 
discharge and at three months after waning of symptoms in unstable angina 
is associated with recurrence of instability during 12 months follow-up. 
J Am Coll Cardiol 1995;Special Issue:250A-251A. abstract.
 
4.
 
Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of 
C-reactive protein and serum amyloid A protein in severe unstable angina. 
N Engl J Med 1994;331:417-24.
 
5.
 
Liuzzo G, Caligiuri G, Grillo RL, et al. 
 
Helicobacter pylori
 
 and cyto-
megalovirus infections are strongly associated with atherosclerosis, but are 
not responsible for the instability of angina. J Am Coll Cardiol 1997;29:
Suppl A:217A. abstract.
Hepatitis-Associated Aplastic Anemia
 
To the Editor:
 
 Brown et al. (April 10 issue)
 
1
 
 summarize
the main features of hepatitis-associated aplastic anemia
and conclude that the hepatitis in patients with this disor-
der is not likely to be caused by any of the known hepatitis
viruses, including hepatitis G virus (HGV). These findings
support recent reports questioning the role of HGV in liv-
er disease.
 
2,3
 
 In their discussion, Brown et al. also mention
that HGV did not appear to cause aplastic anemia.
The article by Brown et al. addresses two different is-
sues: the role of HGV in causing liver disease and the role
of HGV in causing aplastic anemia. We agree that HGV is
most likely not associated with any liver disease. However,
we would like to caution against premature conclusions re-
garding the role of HGV in causing aplastic anemia. The
authors studied serum samples from only 10 patients with
hepatitis-associated aplastic anemia and did not report on
the prevalence of HGV in serum samples from patients
with aplastic anemia not associated with hepatitis.
We have studied the prevalence of HGV RNA in a well-
characterized cohort of 16 patients with hepatitis-associ-
ated aplastic anemia,
 
4
 
 as well as 47 concurrent patients
with idiopathic aplastic anemia not related to hepatitis,
who were matched for age, year of transplantation, and
transfusion status. Our results confirmed that transfusions
were the main source of HGV RNA in serum from both
patients with hepatitis-associated aplastic anemia and those
with idiopathic aplastic anemia (26.1 percent of 23 pa-
tients without transfusions and 67.5 percent of 40 with
transfusions had positive tests for HGV RNA, P
 

 
0.001).
However, there was also an increased prevalence of HGV
RNA in serum from patients with aplastic anemia who did
not receive transfusions (26.1 percent), whether or not the
anemia was associated with hepatitis (2 of 4 patients with
hepatitis-associated aplastic anemia and 4 of 19 with idio-
pathic aplastic anemia had HGV RNA), as compared with
the prevalence (1.7 percent) in serum from normal blood
donors.
 
5
 
 These results suggest a possible role of HGV in
the development of aplastic anemia in some patients. The
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findings also underscore the need for prospective studies
of patients who have not received transfusions, in order to
investigate the possible etiologic role of HGV in aplastic
anemia.
H
 
ANS
 
-P
 
ETER
 
 K
 
IEM
 
, M.D.
R
 
AINER
 
 S
 
TORB
 
, M.D.
G
 
EORGE
 
 B. M
 
C
 
D
 
ONALD
 
, M.D.
 
Fred Hutchinson Cancer Research Center
Seattle, WA 98104
 
1.
 
Brown KE, Tisdale J, Barrett AJ, Dunbar CE, Young NS. Hepatitis-
associated aplastic anemia. N Engl J Med 1997;336:1059-64.
 
2.
 
Alter MJ, Gallagher M, Morris TT, et al. Acute non-A–E hepatitis in 
the United States and the role of hepatitis G virus infection. N Engl J Med 
1997;336:741-6.
 
3.
 
Alter HJ, Nakatsuji Y, Melpolder J, et al. The incidence of transfusion-
associated hepatitis G virus infection and its relation to liver disease. 
N Engl J Med 1997;336:747-54.
 
4.
 
Kiem H-P, McDonald GB, Myerson D, et al. Marrow transplantation 
for hepatitis-associated aplastic anemia: a follow-up of long-term survivors. 
Cesk Marfologie 1996;2:93-9.
 
5.
 
Kiem H-P, Myerson D, Spurgeon CL, Leisenring W, Storb R, 
McDonald GB. Prevalence of hepatitis G virus in patients with aplastic 
anemia. Blood (in press).
 
The authors reply:
 
To the Editor:
 
 A possible relation between hepatitis GB
virus C (GBV-C), also known as HGV, and aplastic anemia
was first suggested by the reports of viremia in a few pa-
tients with bone marrow failure who had apparently not
received transfusions at the time.
 
1,2
 
 Kiem et al. report vi-
remia in two additional patients with hepatitis-associated
aplastic anemia and four with idiopathic aplastic anemia.
Although the specific viral cause of post-hepatitis aplastic
anemia was not a major subject of our article, we have per-
formed more extensive investigations of the relation of
GBV-C to aplastic anemia.
GBV-C viral sequences were present in blood samples
from 26 percent of 57 patients with aplastic anemia, as
compared with 23 percent of 52 controls who had received
multiple transfusions.
 
3
 
 Similar results have been reported
by Moriyama et al.
 
4
 
 for patients with aplastic anemia and
by other groups for patients who have received multiple
blood transfusions because of other diseases. We would
be interested to know whether Kiem et al. have deter-
mined the rate of hepatitis G viremia in controls with mul-
tiple transfusions. Gene-amplification techniques must be
carefully controlled because of the susceptibility to con-
tamination. Furthermore, in our experience some of the
primers and probes used to detect HGV also have positive
results in specimens containing 
 
Escherichia coli
 
 DNA se-
quences.
Neither we nor Moriyama et al. found GBV-C in pa-
tients with aplastic anemia who had not received transfu-
sions. However, GBV-C is not transmitted only as a result
of blood transfusion. The virus is highly prevalent in some
normal populations: we found that almost 6 percent of nor-
mal Vietnamese persons had viral sequences in plasma,
 
5
 
and a similar proportion of normal American children may
also have viremia (unpublished data).
Efforts to establish a relation between GBV-C and any
disease have been frustrating. A member of the expanding
Flaviviridae family has been proposed as a candidate for a
viral cause of aplastic anemia.
 
6
 
 However, GBV-C does not
appear to be the agent responsible for either the common
form of fulminant hepatitis of childhood or seronegative
acute “viral” hepatitis. In our opinion, these syndromes
and hepatitis-associated aplastic anemia probably share a
single infectious cause. Hepatitis viruses commonly “trav-
el” together, and GBV-C viremia may reflect exposure to
another, as yet undiscovered pathogenic hepatitis virus.
Caution is indicated in the interpretation of laboratory
results until we have a better understanding of GBV-C in-
fection in humans and especially of the importance of vi-
remia in apparently well adults and children.
K
 
EVIN
 
 E. B
 
ROWN
 
, M.D.
N
 
EAL
 
 S. Y
 
OUNG
 
, M.D.
 
National Heart, Lung, and Blood Institute
Bethesda, MD 20892
 
1.
 
Byrnes JJ, Banks AT, Piatack M Jr, Kim JP. Hepatitis G-associated aplas-
tic anaemia. Lancet 1996;348:472.
 
2.
 
Zaidi Y, Chapman CS, Myint S. Aplastic anaemia after HGV infection. 
Lancet 1996;348:471-2.
 
3.
 
Brown KE, Wong S, Young NS. Prevalence of GBV-C/HGV, a novel 
“hepatitis” virus, in patients with aplastic anaemia. Br J Haematol 1997;97:
492-6.
 
4.
 
Moriyama K, Okamura T, Nakano S. Hepatitis GB virus C genome in 
the serum of aplastic anaemia patients receiving frequent blood transfu-
sions. Br J Haematol 1997;96:864-7.
 
5.
 
Brown KE, Wong S, Buu M, Binh TV, Be TV, Young NS. High preva-
lence of GB virus C/hepatitis G virus in healthy persons in Ho Chi Minh 
City, Vietnam. J Infect Dis 1997;175:450-3.
6. Young NS. Flaviviruses and bone marrow failure. JAMA 1990;263:
3065-8.
High-Dose Pulsed Dexamethasone for Immune 
Thrombocytopenia
To the Editor: An important and unresolved problem is
the treatment of patients with idiopathic thrombocytope-
nic purpura in whom severe thrombocytopenia persists de-
spite splenectomy. In the June 2, 1994, issue, Andersen
reported excellent results in 10 patients with refractory id-
iopathic thrombocytopenic purpura (5 men and 5 wom-
en) who were treated with high-dose dexamethasone.1 In
all the patients who completed six cycles of dexametha-
sone therapy (40 mg daily for 4 consecutive days every 28
days), platelet counts not only increased but remained
above 100109 per liter for at least 6 months after the last
cycle of treatment.
We treated 10 consecutive patients with refractory idio-
pathic thrombocytopenic purpura (Table 1, next page). All
10 patients had undergone splenectomy and had had re-
lapses after several different treatments. The mean (SD)
age of our patients was similar to the mean age of the pa-
tients described by Andersen (3613 and 4112 years,
respectively; P0.05), and the mean duration of disease
was also similar (4314 months and 4622 months, re-
spectively; P0.05).1 All 10 patients underwent six cycles
of the high-dose dexamethasone protocol. The patients
were followed for 10 to 22 months after the completion
of the trial. As Table 1 shows, none of our patients had a
significant increase in the platelet count.
Caulier et al. used a similar protocol,2 and none of their
patients had a stable increase in the platelet count to a level
The New England Journal of Medicine 
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higher than 100109 per liter. We do not think that high-
dose dexamethasone is effective in the treatment of refrac-
tory idiopathic thrombocytopenic purpura. Controlled mul-
ticenter trials may help identify new therapeutic options
for this disease.
HALÛK DEMI.ROG˘LU, M.D.
SEMRA DÜNDAR, M.D.
Hacettepe University Medical School
Ankara, 06100, Turkey
1. Andersen JC. Response of resistant idiopathic thrombocytopenic pur-
pura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994;
330:1560-4. [Erratum, N Engl J Med 1994;331:283.]
2. Caulier MT, Rose C, Roussel MT, Huart C, Bauters F, Fenaux P. Pulsed 
high-dose dexamethasone in refractory chronic idiopathic thrombocytope-
nic purpura: a report on 10 cases. Br J Haematol 1995;91:477-9.
Dr. Andersen replies:
To the Editor: More than four years after the completion
of treatment, 7 of 10 consecutive outpatients with resist-
ant idiopathic thrombocytopenic purpura who were treat-
ed with pulsed high-dose dexamethasone1 remain in com-
plete clinical remission; 2 are in partial remission. One
patient has had a hematologic relapse but remains asympto-
matic. Table 1 (facing page) summarizes these results, as
well as those for 25 additional patients with new-onset,
resistant, or lupus-associated idiopathic thrombocytopenic
purpura treated at Wayne State University. 
Although optimal dosing schedules have not been es-
tablished, it appears likely that a division of the daily dose,
shortened treatment cycles, and the absence of a meaning-
ful rise in the platelet count after three cycles of pulsed
dexamethasone therapy presage a poor response. Regional
or population-based variability in the response rate may re-
flect, in part, genetically conditioned variability in dexa-
methasone clearance2,3 (and Santen RJ: personal commu-
nication). Patients with a relapse after an initial remission
with pulsed dexamethasone often have a response to one
or two retreatment cycles.
Not knowing the actual characteristics of the patients
studied by Demirog˘lu and Dündar, I cannot determine
which, if any, of the above factors may explain the dramat-
ic difference in the response rate. A natural tendency to
use a newly reported regimen to achieve a benefit in pa-
tients with the poorest responses may provide a partial ex-
planation, as may population-based differences in drug
metabolism and availability.
Only randomized, prospective clinical trials in well-char-
acterized patient populations can determine the value of
a treatment for idiopathic thrombocytopenic purpura. A
national multicenter group for the study of idiopathic
thrombocytopenic purpura has been formed to examine
critically, in patients with several different categories of im-
mune thrombocytopenia, response rates to both conven-
tional and newer therapies. The initial comparison will be
between conventional prednisone therapy and pulsed-dex-
amethasone therapy in obviating the need for splenectomy
in patients with newly diagnosed idiopathic thrombocyto-
penic purpura.
JUDITH C. ANDERSEN, M.D.
Harper Hospital
Detroit, MI 48201
*Pred denotes prednisone, splen splenectomy, vcr vincristine, aza azathioprine, dan danazol, cyc cyclophosphamide, and IVIG intravenous
immune globulin. For patients receiving associated therapy, the drugs were tapered and discontinued after the first cycle of pulsed high-dose
dexamethasone.
†There was an initial response followed by a relapse.
‡There was no response.
TABLE 1. CHARACTERISTICS OF THE PATIENTS AND PLATELET COUNTS BEFORE AND AFTER THE COMPLETION 
OF PULSED HIGH-DOSE DEXAMETHASONE THERAPY AND AT THE END OF FOLLOW-UP.
PATIENT
NO.
AGE
(YR) SEX
DURATION OF
DISEASE (MO) THERAPY* PLATELET COUNT (10
9/LITER)
PRIOR ASSOCIATED
BEFORE
THERAPY AT 6 MO
AT END
OF FOLLOW-UP
(MO)
1 32 M 28 Pred,† splen,† vcr,† aza‡ None 21 27 25 (22)
2 23 F 39 Pred,† splen,† dan,‡ cyc‡ Pred 14 17 16 (20)
3 41 F 58 Pred,‡ splen,† vcr,‡ IVIG† None 17 15 14 (19)
4 29 M 43 Pred,‡ splen,‡ vcr,‡ aza,‡ IVIG‡ None 15 20 18 (17)
5 36 M 35 Pred,‡ splen,† vcr,† cyc‡ None 28 36 34 (16)
6 65 F 46 Pred,† splen,† aza,† IVIG† None 22 27 28 (14)
7 31 F 51 Pred,† splen,† cyc,‡ IVIG‡ Pred 17 16 14 (14)
8 23 M 26 Pred,† splen,† aza,‡ IVIG† cyc 11 15 15 (12)
9 30 F 30 Pred,‡ splen,‡ vcr,‡ dan‡ Pred 19 18 21 (11)
10 52 M 71 Pred,‡ splen,‡ dan,‡ cyc‡ None 12 16 16 (10)
Mean
SD
SE
36.2
13.2
4.2
—
—
—
42.7
14.3
4.5
—
—
—
—
—
—
17.6
5.1
1.6
20.7
7
2.2
20.1
6.8
2.1
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1. Andersen JC. Response of resistant idiopathic thrombocytopenic pur-
pura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994;
330:1560-4. [Erratum, N Engl J Med 1994;331:283.]
2. Santen R, Lipton A. Successful medical adrenalectomy — the role of 
altered drug metabolism. Clin Res 1973;21:653. abstract.
3. Lipton A, Santen RJ. Medical adrenalectomy using aminoglutethimide 
and dexamethasone in advanced breast cancer. Cancer 1974;33:503-12.
Stenting for Carotid Stenosis?
To the Editor: I was disappointed by “A Common Clin-
ical Conundrum” (April 3 issue).1 This Clinical Problem-
Solving article discussed a procedure — extracranial ca-
rotid-artery stenting — that is experimental, has not been
validated by published multicenter trials, and is not widely
available in community hospitals. In their discussion of
success rates, complications, and long-term patency, the
authors do not cite any article in a peer-reviewed journal
to support their claims, only sketchy abstracts presented at
a scientific meeting.2,3 They cite no study to prove cost ef-
fectiveness, referring only to their own unpublished “pre-
liminary” work. The inclusion of carotid stenting in the
Clinical Problem-Solving article has given the technique
an imprimatur that it does not yet deserve.
ROBERT L. MITTL, JR., M.D.
Charlotte Radiology
Charlotte, NC 28236-6937
1. Gray WA, DuBroff RJ, White HJ. A common clinical conundrum. 
N Engl J Med 1997;336:1008-11.
2. Iyer SS, Roubin GS, Yadav JS, et al. Angioplasty and stenting for extra-
cranial carotid stenosis: multicenter experience. Circulation 1996;94:Suppl 
I:I-58. abstract.
3. Yadav JS, Roubin GS, Vitek J, et al. Late outcome after carotid angio-
plasty and stenting. Circulation 1996;94:Suppl I:I-58. abstract.
To the Editor: In “A Common Clinical Conundrum”
Gray and associates describe a patient with ischemic heart
disease and asymptomatic carotid stenosis who underwent
staged carotid-artery stenting and coronary bypass. We as-
sert that the data they cite on morbidity after carotid stent-
ing and endarterectomy are not representative. The data
were obtained from a study by Iyer and colleagues, pub-
lished as an abstract, in which the risk of stroke associated
with carotid stenting was given as 3.3 percent.1 Other ar-
ticles by the same group have reported stroke rates be-
tween 6 percent2 and 8 percent.3 At follow-up, which was
limited to six months, 6 percent of patients required rein-
tervention (endarterectomy or balloon angioplasty) for
stent deformation or restenosis.3
The widely published estimates of the risk of neurologic
events after carotid endarterectomy from the Asymptomat-
ic Carotid Atherosclerosis Study and the North American
Symptomatic Carotid Endarterectomy Trial (NASCET)
are 2.4 percent for asymptomatic patients4 and 5.5 percent
for patients with symptoms (transient in two thirds of the
latter).5
Furthermore, the arteriogram presented as proof of tech-
nical success after carotid stent placement demonstrated
near-occlusion of the external carotid artery by the stent.
This result would be unacceptable after endarterectomy
because of the extensive cerebral collaterals dependent on
this vessel should restenosis develop in the internal carotid
artery.
In summary, the authors have described the use of ca-
rotid stenting in a high-risk patient with coronary artery
*Group 1 consists of the patients with resistant idiopathic thrombocytopenic purpura who were
treated at Wayne State University and described in 1994.1 The updated results are shown. Group 2
consists of patients subsequently treated at Wayne State University.
†These patients had symptomatic relapses of idiopathic thrombocytopenic purpura and had re-
ceived previous outpatient treatment with more than two regimens (with or without splenectomy).
‡These patients had previously untreated idiopathic thrombocytopenic purpura, which had been
diagnosed within the previous three months.
§These patients had immune thrombocytopenia in the setting of active systemic lupus erythema-
tosus (with or without splenectomy).
TABLE 1. RATES OF RESPONSE TO PULSED HIGH-DOSE DEXAMETHASONE.
GROUP*
NO. OF
PATIENTS FOLLOW-UP PLATELET COUNT (109/liter) COMMENTS
150 50–150 50
mo no. of patients (%)
1 10 50 7 (70) 2 (20) 1 (10) Resistant idiopathic 
thrombocytopenic 
purpura†
2a 15 17 7 (47) 5 (33) 3 (20) Resistant idiopathic 
thrombocytopenic 
purpura†
2b 8 15 6 (75) 2 (25) 0 New-onset idiopathic 
thrombocytopenic 
purpura‡
2c 2 26 0 0 2 (100) Lupus-associated idio-
pathic thrombocy-
topenic purpura§
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disease. Undoubtedly, appropriate indications for this new
technique will emerge for selected patients. However, at the
present time, owing to the lack of long-term follow-up, in-
creased risk of neurologic events, and uncertainties regard-
ing its durability and long-term costs, carotid stenting is
not yet appropriate for the routine management of carotid
stenosis.
JAMES M. ESTES, M.D.
MAGRUDER C. DONALDSON, M.D.
ANTHONY D. WHITTEMORE, M.D.
Brigham and Women’s Hospital
Boston, MA 02115
1. Iyer SS, Roubin GS, Yadav JS, et al. Angioplasty and stenting for extra-
cranial carotid stenosis: multicenter experience. Circulation 1996;94:Suppl 
I:I-58. abstract.
2. Roubin GS, Yadav S, Iyer SS, Vitek J. Carotid stent-supported angio-
plasty: a neurovascular intervention to prevent stroke. Am J Cardiol 1996;
78:Suppl 3A:8-12.
3. Yadav JS, Roubin GS, Iyer S, et al. Elective stenting of the extracranial 
carotid arteries. Circulation 1997;95:376-81.
4. Hobson RW II, Weiss DG, Fields WS, et al. Efficacy of carotid endar-
terectomy for asymptomatic carotid stenosis. N Engl J Med 1993;328:
221-7.
5. North American Symptomatic Carotid Endarterectomy Trial Col-
laborators. Beneficial effect of carotid endarterectomy in symptomatic
patients with high-grade carotid stenosis. N Engl J Med 1991;325:445-
53.
The authors reply:
To the Editor: We strongly agree with Dr. Mittl — at this
time, carotid stenting should be performed only under a
strict investigational protocol with appropriate multidisci-
plinary support and assessment. Its experimental nature
should be clearly explained to potential patients, as should
alternatives such as medical or surgical management. We
disagree, however, that there are no peer-reviewed data
supporting carotid stenting. At least one published article,
by Yadav et al.,1 summarizes the experience with the pro-
cedure.
The representation by Estes et al. of the stroke rates in
the Yadav article, which is the largest published series of its
type, may be misleading. Of 126 stents implanted, there
were seven strokes related to the procedure. One was a ma-
jor stroke, and six were minor. A minor stroke was defined
as modest deficits that resolved within a week. Because all
these patients met NASCET exclusion criteria, they would
not have been included in NASCET. Similar stroke rates
were observed in NASCET, which involved a more highly
selected patient population than that in the stent study.2
In addition, complications of surgery in NASCET, includ-
ing cranial-nerve palsy (7.6 percent), wound hematoma
(5.5 percent), and infection (3.4 percent), were not seen
after carotid stenting. Although the rates of restenosis af-
ter carotid surgery range from 5 to 19 percent,3,4 only
three patients received treatment for asymptomatic reste-
nosis after carotid stenting in the study by Yadav et al.1
WILLIAM A. GRAY, M.D.
ROBERT J. DUBROFF, M.D.
HARVEY J. WHITE, JR., M.D.
Southwest Cardiology Associates
Albuquerque, NM 87102
1. Yadav JS, Roubin GS, Iyer S, et al. Elective stenting of the extracranial 
carotid arteries. Circulation 1997;95:376-81.
2. North American Symptomatic Carotid Endarterectomy Trial Collabo-
rators. Beneficial effect of carotid endarterectomy in asymptomatic patients 
with high-grade carotid stenosis. N Engl J Med 1991;325:445-53.
3. Zierler RE, Bandyk DF, Thiele BL, Strandness E Jr. Carotid artery ste-
nosis following endarterectomy. Arch Surg 1982;117:1408-15.
4. Edwards WH Jr, Edwards WH Sr, Mulherin JL Jr, Martin RS III. Re-
current carotid artery stenosis: resection with autogenous vein replace-
ment. Ann Surg 1989;209:662-9.
Osteomyelitis
To the Editor: Several comments are in order for the
U.S. audience of the excellent review of osteomyelitis by
Lew and Waldvogel (April 3 issue),1 especially regarding
Table 2. Many infectious-disease specialists prescribe both
penicillin and nafcillin every four hours, rather than every
six hours as suggested in the article. These beta-lactams
have a short half-life, and consideration should certainly
be given to using the higher dose (i.e., a shorter interval
between doses). Clindamycin can be given effectively ev-
ery eight hours because of its prolonged half-life. No clin-
ical advantage has ever been proved for the administration
of 600 mg every six hours as opposed to every eight
hours. A dosing regimen involving six-hour intervals is
more toxic, more expensive, and certainly much more dif-
ficult to give on an outpatient basis. Ciprofloxacin, at dos-
es of 750 mg every 8 to 12 hours, should also be consid-
ered as an acceptable therapy for serratia or pseudomonas.
(It was only listed as the treatment of choice for enteric
gram-negative rods in Table 2.) Amoxicillin–clavulanate is
not available in the United States as an intravenous prep-
aration; cloxacillin is not available at all, although diclox-
acillin is. Numerous other drugs can be substituted for
intravenous amoxicillin–clavulanate, including ampicillin–
sulbactam, ticarcillin–clavulanate, piperacillin–tazobactam,
and a third-generation cephalosporin plus metronidazole.
Other potential options in the United States for the treat-
ment of methicillin-resistant Staphylococcus aureus in cases
in which intravenous vancomycin cannot be used include
agents such as trimethoprim–sulfamethoxazole, clinda-
mycin, minocycline, and a quinolone with or without ri-
fampin.
AARON E. GLATT, M.D.
Catholic Medical Center of Brooklyn and Queens
Jamaica, NY 11432
1. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997;336:999-
1007.
To the Editor: Drs. Lew and Waldvogel barely comment-
ed on the usefulness of oral antibiotics in the treatment of
this infection. Certainly, the use of oral antimicrobial ther-
apy, when based on sound pharmacodynamic principles, is
a “current concept” that we should not ignore.
Although oral beta-lactam agents have limited bioavail-
ability, as the authors pointed out, they have been used
quite successfully in the treatment of osteomyelitis and
septic arthritis, when given in appropriate doses.1 Al-
though the quinolones have revolutionized the approach
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to treating severe infections in the outpatient setting, oth-
er oral agents such as clindamycin, trimethoprim–sulfa-
methoxazole, metronidazole, doxycycline, and minocy-
cline also offer excellent bioavailability, favorable dosing
schedules, good tissue penetration, long-term tolerability,
and low cost. . . .
KEVIN W. SHEA, M.D.
Carolinas Hospital System
Florence, SC 29501
1. Black J, Hunt TL, Godley PJ, Matthew E. Oral antimicrobial therapy 
for adults with osteomyelitis or septic arthritis. J Infect Dis 1987;155:968-
72. [Erratum, J Infect Dis 1987;156:541.]
The authors reply:
To the Editor: Dr. Glatt makes some valuable comments
on treatment recommendations. Table 2 of our article was
not exhaustive, and obviously other antibiotics may be
prescribed as he suggests. Parenteral penicillins may indeed
be prescribed every four to six hours, although in some cas-
es such as the antipseudomonas penicillins the interval be-
tween doses can be extended successfully to eight hours.1
Clindamycin may be prescribed every six to eight hours
(which is more convenient for oral administration) as in-
dicated by the severity of symptoms and infecting micro-
organisms. In our opinion the glycopeptides are often the
only available therapeutic agents for methicillin-resistant
Staphylococcus aureus. The other alternatives proposed (tri-
methoprim–sulfamethoxazole and minocycline) may be
used for minor infections with methicillin-resistant S. au-
reus. Unfortunately, a large proportion of methicillin-resist-
ant S. aureus are resistant to quinolones. 
Dr. Shea raises the issue of the role of oral antibiotics in
the treatment of osteomyelitis. Although oral treatment of
acute osteomyelitis in children has been an accepted ap-
proach for many years, the approach to the treatment of
acute or chronic osteomyelitis in adults has traditionally
been intravenous. In our opinion, for beta-lactam antibi-
otics intravenous therapy remains the standard for osteo-
myelitis in adults. Among other agents, clindamycin may
be a reasonable alternative for sequential intravenous–oral
therapy because of its excellent bone penetration and good
bioavailability.
Several good-quality comparative trials have shown the
equivalence of oral quinolones and parenteral therapy. We
have performed a cumulative analysis of published com-
parative trials of quinolones to treat osteomyelitis.2 With
oral ciprofloxacin, success rates of 92 percent for Entero-
bacteriaceae (even higher if serratia are excluded), 72
percent for Pseudomonas aeruginosa, and 75 percent for
S. aureus were found.2 On treatment with quinolones os-
teomyelitis due to P. aeruginosa or S. aureus was associat-
ed with a fourfold increase in the failure rate, as compared
with the failure rate in osteomyelitis due to other patho-
gens.2 Thus, in the case of osteomyelitis due to Entero-
bacteriaceae the success rate is so good that no further tri-
als appear to be necessary. This is not the case for S. aureus
and P. aeruginosa. 
Figure 2B of our article was printed upside down.
Therefore, the T1-weighted image appears on the right
and the image after the intravenous injection of gadolin-
ium on the left.
DANIEL P. LEW, M.D.
FRANCIS WALDVOGEL, M.D.
Geneva University Hospital
CH-1211 Geneva 14, Switzerland
1. Quintiliani R, Nightingale CH, Sullivan MC. Use of pharmacodynamic 
concepts in developing a cost-effective dosing method for piperacillin. Clin 
Ther 1993;15:Suppl A:44-9.
2. Lew DP, Waldvogel FA. Quinolones and osteomyelitis: state-of-the-art. 
Drugs 1995;49:Suppl 2:100-1.
Cellulitis Due to Botfly Larvae
To the Editor: I report a case of cellulitis complicated by
what turned out to be botfly larvae.
A 36-year-old woman presented with erythema, swell-
ing, and pain in both shins. The lesions had developed two
weeks after she returned from Peru. Cellulitis was diag-
nosed, and cephalexin was prescribed. The cellulitis im-
proved somewhat, but two weeks after the initial presen-
tation new lesions developed. On examination, the patient
had seven tender, erythematous, indurated subcutaneous
lesions 2 to 3 cm in diameter, each with a central punc-
tum. A course of dicloxacillin was started. The same night,
the patient saw a larva crawl out of a lesion (Fig. 1). She
called for advice and was told to apply petroleum jelly to
force the other larvae out for air. She tried this briefly, but
became impatient and eventually squeezed out the larvae
manually. She obtained a total of seven larvae in this man-
Figure 1. Botfly Larva from the Patient (75).
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ner, which were identified as Dermatobia hominis, com-
monly called the human botfly.
D. hominis has a fascinating life cycle.1 It is found widely
in humid areas of Mexico, Central America, and South
America. Its larvae can survive only in vertebrate tissue; in-
festation with them is known as myiasis. The adult female
botfly deposits eggs on the abdomen of a bloodsucking fly
or mosquito, which in turn deposits the eggs on an animal
host. The growth of each larva can provoke severe ulcer-
ation and secondary infection. Once mature, the larvae
erupt through the host’s skin and fall to the ground, where
they develop into pupae and subsequently into adult flies.
Myiasis has been reported previously,2-4 but this case was
remarkable in two respects. The first was that multiple lar-
vae were present. Previous reported cases have involved in-
festations of at most a few larvae each. The presence of
seven larvae in this patient should alert practitioners to
look for multiple sites of infestation.
The second interesting aspect was the mode of treat-
ment. Standard recommendations are to apply petroleum
jelly or raw meat to draw the larvae out,5 or to extract
them with mosquito forceps. Nowhere does the literature
recommend simply squeezing them out. In fact, one may
wonder whether such an approach might worsen the prob-
lem by crushing the larvae. However, in this patient the
procedure was expedient and effective for all seven lesions,
and she recovered without sequelae.
RACHEL L. CHIN, M.D.
San Francisco General Hospital
San Francisco, CA 94110
1. Farrell LD, Wong RK, Manders EK, Olmstead PM. Cutaneous myiasis. 
Am Fam Physician 1987;35:127-33.
2. File TM Jr, Thomson RB Jr, Tan JS. Dermatobia hominis dermal myiasis: 
a furuncular lesion in a world traveler. Arch Dermatol 1985;121:1195-6.
3. Arthropods and human disease. In: Markell EK, Voge M, John DT. 
Medical parasitology. 7th ed. Philadelphia: W.B. Saunders, 1992:353-6.
4. Minton SA, Bechtel HB. Arthropod envenomation and parasitism. In: 
Auerbach PS, ed. Wilderness medicine: management of wilderness and en-
vironmental emergencies. 3rd ed. St. Louis: Mosby, 1995:755-7.
5. Rooney S, Kerrigan D. Bot-fly bite. Postgrad Med J 1993;69:411.
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